Jack Allen
Stock Analyst at Baird
(1.54)
# 3,499
Out of 5,152 analysts
43
Total ratings
41.18%
Success rate
-7.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACLX Arcellx | Downgrades: Neutral | $106 → $115 | $114.36 | +0.56% | 6 | Feb 23, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $52 → $44 | $57.33 | -23.25% | 3 | Nov 11, 2025 | |
| VOR Vor Biopharma | Upgrades: Outperform | $20 → $64 | $14.56 | +339.56% | 5 | Oct 15, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Outperform | $7 → $12 | $4.49 | +167.26% | 5 | Oct 2, 2025 | |
| FATE Fate Therapeutics | Maintains: Neutral | $5 → $4 | $1.38 | +189.86% | 2 | May 14, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $12 → $9 | $2.31 | +289.61% | 3 | May 14, 2025 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $80 → $40 | $10.95 | +265.30% | 2 | Nov 15, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $24 → $18 | $13.15 | +36.88% | 2 | Oct 25, 2024 | |
| TIL Instil Bio | Reiterates: Outperform | $180 | $8.53 | +2,010.20% | 9 | Sep 16, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Outperform | $8 | $0.39 | +1,946.04% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $84 | $31.98 | +162.66% | 1 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $1.84 | +171.74% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.70 | - | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $9 | $3.93 | +129.01% | 1 | Oct 7, 2021 |
Arcellx
Feb 23, 2026
Downgrades: Neutral
Price Target: $106 → $115
Current: $114.36
Upside: +0.56%
CRISPR Therapeutics AG
Nov 11, 2025
Maintains: Neutral
Price Target: $52 → $44
Current: $57.33
Upside: -23.25%
Vor Biopharma
Oct 15, 2025
Upgrades: Outperform
Price Target: $20 → $64
Current: $14.56
Upside: +339.56%
Taysha Gene Therapies
Oct 2, 2025
Maintains: Outperform
Price Target: $7 → $12
Current: $4.49
Upside: +167.26%
Fate Therapeutics
May 14, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $1.38
Upside: +189.86%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $12 → $9
Current: $2.31
Upside: +289.61%
MiNK Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $80 → $40
Current: $10.95
Upside: +265.30%
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $24 → $18
Current: $13.15
Upside: +36.88%
Instil Bio
Sep 16, 2024
Reiterates: Outperform
Price Target: $180
Current: $8.53
Upside: +2,010.20%
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $0.39
Upside: +1,946.04%
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $31.98
Upside: +162.66%
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $1.84
Upside: +171.74%
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $3.70
Upside: -
Oct 7, 2021
Upgrades: Outperform
Price Target: $6 → $9
Current: $3.93
Upside: +129.01%